印度制药出口在2024-25年达到305亿美元,上升9.4%,以美国和欧洲需求为首。 India’s pharma exports hit $30.5 billion in 2024–25, up 9.4%, led by U.S. and European demand.

印度的制药出口在2024-25财政年度达到30.47亿美元,比上一年增长了9.4%,美国和欧洲是顶尖市场。 India's pharmaceutical exports reached $30.47 billion in fiscal year 2024–25, a 9.4% rise from the prior year, with the U.S. and Europe as top markets. 该部门按数量和价值分别占世界第三大和第十四大,包括3 000多家公司和10 500个制造单位,向200多个国家供应药品。 The sector, the world’s third-largest by volume and 14th by value, includes over 3,000 companies and 10,500 manufacturing units, supplying medicines to over 200 countries. 国内市场价值600亿美元,预计到2030年将达1 300亿美元。 The domestic market, valued at $60 billion, is projected to reach $130 billion by 2030. 政府倡议,包括新的贸易协定和促进生物学和生物类似学创新的努力,旨在扩大全球出口和加强监管合作。 Government initiatives, including new trade agreements and efforts to boost innovation in biologics and biosimilars, aim to expand global exports and strengthen regulatory cooperation.